Federal judge asks DEA for show cause information; DEA claims millions of suspicious orders
After Cardinal Health’s Lakeland, FL, DC had its controlled-substances distribution license lifted on Feb. 3 (read back story here), and Cardinal obtained a temporary restraining order on the same day to continue operations, the regulatory dispute entered federal court on Feb. 13 under DEA’s standing process of enforcing distribution licenses. In the interim, DEA posted a news release claiming that two CVS pharmacies in Florida together had ordered over 3 million doses of controlled substances (mostly opioids) in 2011, while an average US pharmacy would order only 69,000. Also, Cardinal has been operating under an existing Memorandum of Agreement (MOA) since October 2008 (when a previous DEA enforcement action was finalized for that facility) and, in essence, should have known better.
The CVS pharmacies in question also sought, and won, temporary restraining orders against DEA. Two other pharmacies are apparently now without their controlled-substances licenses.
On Feb. 13, the federal judge asked DEA to provide more substantive information, with a deadline of Feb. 24. While contesting the DEA action, Cardinal issued a statement pointing out that “simple averages” of drug-ordering volumes are not a meaningful way to assess suspicious ordering patterns. “This one-size-fits-all approach oversimplifies the difficult and complicated process that is required of distributors that try to strike the balance Congress mandated between ensuring medications don’t fall into the wrong hands, while at the same time ensuring those medications are available for legitimate patient care.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.